Johansen NJ, Dejgaard TF, Lund A et al (2020) Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
Despite these limitations, the FDA database offers real-world data on clinically relevant adverse events associated with medication use, broadening the pharmacovigilance landscape
GLP1s have become one of the most talkedabout weight loss treatments over the last year, but much of the conversation has focused on women
The evidence currently available indicates that GLP-1 RA could add to the arsenal available to address persistent gaps in the care of people living with T2DM with, or at the risk of, developing CKD and to reduce the residual renal risk present in those who have already developed CKD
Rosuvastatin may lead to several side effects, including but not limited to headache, muscle aches, abdominal pain, weakness, nausea, or tiredness
If you are considering GLP-1 therapy, the primary benefits are sustainable weight loss, improved blood sugar, and cardiovascular health